Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/50548
Campo DC Valoridioma
dc.contributor.authorRomagnoli, Romeoen_US
dc.contributor.authorBaraldi, Pier Giovannien_US
dc.contributor.authorSalvador, Maria Kimatraien_US
dc.contributor.authorCamacho, M. Encarnacionen_US
dc.contributor.authorBalzarini, Janen_US
dc.contributor.authorBermejo, Jaimeen_US
dc.contributor.authorEstévez, Franciscoen_US
dc.contributor.otherCamacho, M. Encarnacion-
dc.contributor.otherBaraldi, Pier Giovanni-
dc.contributor.otherRomagnoli, Romeo-
dc.contributor.otherEstevez, Francisco-
dc.date.accessioned2018-11-24T16:54:20Z-
dc.date.available2018-11-24T16:54:20Z-
dc.date.issued2013en_US
dc.identifier.issn0223-5234en_US
dc.identifier.urihttp://hdl.handle.net/10553/50548-
dc.description.abstractHybridization of two different bioactive molecules with different mechanism of action is one of the methods that are being adopted to treat cancer. Molecules bearing a thiazolidine-2,4-dione scaffold have been recognized as antineoplastic agents with a broad spectrum of activity against many cancer cell lines. In this manuscript we have described the synthesis and biological evaluation of two series of N-3-substituted-5-arylidene thiazolidine-2,4-diones, bearing the alpha-bromoacryloylamido moiety at the para- or meta-position on the phenyl of the arylidene portion. We have observed that selected compounds 5a, 5c and 5g suppress proliferation of human myeloid leukaemia HL-60 and U937 cells by triggering morphological changes and internucleosomal DNA fragmentation, which are well-known features of apoptosis. Finally, our results indicated that the investigated compounds induced apoptotic cell death through a mechanism that involved activation of multiple caspases and was also associated with the release of cytochrome c from the mitochondria.en_US
dc.languageengen_US
dc.relationEvaluación de Potenciales Compuestos Antileucémicos.en_US
dc.relation.ispartofEuropean Journal of Medicinal Chemistryen_US
dc.sourceEuropean Journal of Medicinal Chemistry[ISSN 0223-5234],v. 63, p. 544-557en_US
dc.subject32 Ciencias médicasen_US
dc.subject320713 Oncologíaen_US
dc.subject.otherHuman Leukemia-Cellsen_US
dc.subject.otherCytochrome-Cen_US
dc.subject.otherCancer Cellsen_US
dc.subject.otherCaspasesen_US
dc.subject.otherDeathen_US
dc.subject.otherBrostallicinen_US
dc.subject.otherDerivativesen_US
dc.subject.otherInhibitionen_US
dc.subject.otherMechanismsen_US
dc.subject.otherApoptosisen_US
dc.titleAnticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dioneen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ejmech.2013.02.030en_US
dc.identifier.scopus84875332058-
dc.identifier.isi000322855400052-
dcterms.isPartOfEuropean Journal Of Medicinal Chemistry-
dcterms.sourceEuropean Journal Of Medicinal Chemistry[ISSN 0223-5234],v. 63, p. 544-557-
dc.contributor.authorscopusid7101729609-
dc.contributor.authorscopusid7101681318-
dc.contributor.authorscopusid54684944400-
dc.contributor.authorscopusid7102602358-
dc.contributor.authorscopusid36049696300-
dc.contributor.authorscopusid7101636723-
dc.contributor.authorscopusid7003810011-
dc.description.lastpage557en_US
dc.description.firstpage544en_US
dc.relation.volume63en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.identifier.wosWOS:000322855400052-
dc.contributor.daisngid32727-
dc.contributor.daisngid38403-
dc.contributor.daisngid2498213-
dc.contributor.daisngid1068655-
dc.contributor.daisngid233-
dc.contributor.daisngid5695465-
dc.contributor.daisngid384944-
dc.identifier.investigatorRIDG-7916-2015-
dc.identifier.investigatorRIDB-7933-2017-
dc.identifier.investigatorRIDG-9887-2015-
dc.identifier.investigatorRIDK-5125-2014-
dc.description.numberofpages14en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Romagnoli, R-
dc.contributor.wosstandardWOS:Baraldi, PG-
dc.contributor.wosstandardWOS:Salvador, MK-
dc.contributor.wosstandardWOS:Camacho, ME-
dc.contributor.wosstandardWOS:Balzarini, J-
dc.contributor.wosstandardWOS:Bermejo, J-
dc.contributor.wosstandardWOS:Estevez, F-
dc.date.coverdateMarzo 2013en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,209-
dc.description.jcr3,432-
dc.description.sjrqQ1-
dc.description.jcrqQ1-
dc.description.scieSCIE-
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.project.principalinvestigatorEstévez Rosas, Francisco Jesús-
crisitem.author.deptGIR IUIBS: Bioquímica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Bioquímica y Biología Molecular, Fisiología, Genética e Inmunología-
crisitem.author.orcid0000-0002-9728-2774-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameEstévez Rosas, Francisco Jesús-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

55
actualizado el 21-abr-2024

Citas de WEB OF SCIENCETM
Citations

54
actualizado el 25-feb-2024

Visitas

45
actualizado el 02-dic-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.